Movement Alert|Revolution Medicines, Inc. Falls 4.14% in Regular Trading, Post-Earnings Valuation Digestion Pressure Persists

Market Focus11-13

On November 13, Revolution Medicines, Inc. fell 4.14% in Regular Trading, trading at $168.77 per share, with turnover of $30.6172 million.

The clearest catalyst in recent market coverage is continued post-earnings valuation digestion after the company’s third-quarter report, despite results beating expectations and analysts lifting price targets.

Background shows Revolution Medicines, Inc. reported third-quarter EPS of $(1.90), better than the $(2.42) consensus estimate, while revenue was $197.559 million, far above the prior market estimate cited in coverage, though that comparison was flagged as not fully comparable. After the report, RBC raised its target price to $321, JP Morgan lifted its target to $289, and Bank of America maintained a Buy rating with a $274 target, reflecting confidence in Rasonque’s commercialization potential following its approval. Even so, recent coverage indicated that earlier optimism had already been substantially priced in, leaving the shares under near-term valuation pressure.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment